TENX - Catalyst 03/06/2024 - Possible gap fill
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.
This is not a financial advice!
Upcoming catalysts 03/06/2024
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Keep an eye on 5.6 level, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 4.3
TPs approx. 8.3 (gap fill)
Most info on the chart.
Trade carefully!
This is not a financial advice!
Upcoming catalysts 03/06/2024
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Keep an eye on 5.6 level, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 4.3
TPs approx. 8.3 (gap fill)
Most info on the chart.
Trade carefully!
Trade fermée: ordre d’arrêt atteint
Join Discord channel:
whop.com/marketplace/contingent-traders/
contingenttrader.com/
whop.com/marketplace/contingent-traders/
contingenttrader.com/
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.
Join Discord channel:
whop.com/marketplace/contingent-traders/
contingenttrader.com/
whop.com/marketplace/contingent-traders/
contingenttrader.com/
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.